Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial

References

• Xu Y, Gong M, Wang Y, et al. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10(1):334.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• DiNardo D, McNeil MA. Update on breast cancer. J Womens Health (Larchmt). 2023;32(7):736–739. doi: 10.1089/jwh.2023.0213
   PubMed Web of Science ®Google Scholar
• Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi: 10.1016/S0140-6736(16)31891-8
   PubMed Web of Science ®Google Scholar
• Lebert J, Lilly EJ. Developments in the management of metastatic HER2-positive breast cancer: a review. Curr Oncol. 2022;29(4):2539–2549. doi: 10.3390/curroncol29040208
   PubMed Web of Science ®Google Scholar
• Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol. 2020;47(5):259–269. doi: 10.1053/j.seminoncol.2020.07.008
   PubMed Web of Science ®Google Scholar
• Essadi I, Benbrahim Z, Kaakoua M, et al. HER2-positive metastatic breast cancer: available treatments and Current developments. Cancers (Basel). 2023;15(6):1738.
   PubMed Web of Science ®Google Scholar
• Graff SL, Yan F, Abdou Y. Newly approved and emerging agents in HER2-positive metastatic breast cancer. Clin Breast Cancer. 2023;23(7):S1526-8209(23)00108–8. pii. doi: 10.1016/j.clbc.2023.05.003
   Web of Science ®Google Scholar
• Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021;23(1):84. doi: 10.1186/s13058-021-01459-y
   PubMed Web of Science ®Google Scholar
• André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–1785.
   PubMed Web of Science ®Google Scholar
• Narayan P, Dilawari A, Osgood C, et al. US Food and drug Administration approval Summary: Fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023;41(11):2108–2116.
   PubMed Web of Science ®Google Scholar
• Turner HC, Sandmann FG, Downey LE, et al. What are economic costs and when should they be used in health economic studies. Cost Eff Resour Alloc. 2023;21(1):31.
   PubMed Web of Science ®Google Scholar
• He W, Li M, Cao L, et al. Introducing value-based healthcare perspectives into hospital performance assessment: a scoping review. J Evid Based Med. 2023;16(2):200–215.
   PubMedGoogle Scholar
• Rui M, Wang Y, Fei Z, et al. Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):373–380.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• National Bureau of statistics of China(2022). Statistical Bulletin of National economic and Social development of the People’s Republic of China in2022. Available online at https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2022 (Accessed Aug 15, 2023).
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(1):139. doi: 10.1186/1471-2288-11-139
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. PharmacoEconomics. 2014;32(2):101–108. doi: 10.1007/s40273-013-0123-9
   PubMed Web of Science ®Google Scholar
• YaoZH (2023). Drug pice. Available at: https://www.yaozh.com/ (accessed Aug 15, 2023).
   Google Scholar
• Zhan M, Huang Z, Xu T, et al. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front Public Health. 2023;11:1049947. doi: 10.3389/fpubh.2023.1049947
   PubMed Web of Science ®Google Scholar
• Yang J, Han J, Zhang Y, et al. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Front Pharmacol. 2022;13:924126. doi: 10.3389/fphar.2022.924126
   PubMed Web of Science ®Google Scholar
• Huang X, Lin D, Lin S, et al. Cost-effectiveness and value-based pricing of trastuzumab deruxtecan in metastatic breast cancer with low HER2 expression. Clin Breast Cancer. 2023;23(5):508–518.
   PubMed Web of Science ®Google Scholar
• Yue X, Li Y, Wu J, et al. Current development and Practice of Pharmacoeconomic evaluation Guidelines for Universal health coverage in China. Val Health Reg Iss. 2021;24:1–5. doi: 10.1016/j.vhri.2020.07.580
   PubMedGoogle Scholar
• State Administration of Foreign Exchange (2022). Table of conversion rates of various currencies to USD. Available at: Accessed Aug 15, 2023. https://data.stats.gov.cn/english/easyquery.htm?cn=C01
   Google Scholar
• Wang H, Wang Y, Gong R, et al. Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China. Ann Palliat Med. 2021;10(11):11382–11393. doi: 10.21037/apm-21-2412
   PubMed Web of Science ®Google Scholar
• Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021;18(3):900–909.
   PubMed Web of Science ®Google Scholar
• Nie T, Blair HA. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer. Target Oncol. 2023;18(3):463–470. doi: 10.1007/s11523-023-00971-9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Wang M, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: a cost-effectiveness analysis. Breast. 2022;66:191–198. doi: 10.1016/j.breast.2022.10.010
   PubMed Web of Science ®Google Scholar
• Almaktoom AT. Health care overbooking cost minimization model. Heliyon. 2023;9(8):e18753. doi: 10.1016/j.heliyon.2023.e18753
   PubMed Web of Science ®Google Scholar
• Xu Y, Greene TH, Bress AP, et al. Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. Biometrics. 2022;78(1):337–351.
   PubMed Web of Science ®Google Scholar
• Yang F, Duarte A, Walker S, et al. Uncertainty analysis in Intervention impact on health inequality for resource allocation decisions. Med Decis Making. 2021;41(6):653–666.
   PubMed Web of Science ®Google Scholar
• Rivers Z, Roth JA, Wright W, et al. Translating an economic analysis into a tool for public health resource allocation in cancer survivorship. MDM Policy Pract. 2023;8(1):23814683231153378.
   Google Scholar
• Assor Y, Greenberg D. Public legitimacy of healthcare resource allocation committees: lessons learned from assessing an Israeli case study. BMC Health Serv Res. 2022;22(1):737. doi: 10.1186/s12913-022-07992-6
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.
   PubMed Web of Science ®Google Scholar
• Yang C, Brezden-Masley C, Joy AA, et al. Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Ther Adv Med Oncol. 2023;15:17588359231175440. doi: 10.1177/17588359231175440
   Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–117.
   PubMed Web of Science ®Google Scholar
• Yuan J, Li M, Lu ZK. National value-based pricing negotiation for oncology drugs - lessons from China. Nat Rev Clin Oncol. 2023;20(8):501–502. doi: 10.1038/s41571-023-00769-8
   PubMed Web of Science ®Google Scholar
• Mingge X, Jingyu W, Qi L, et al. Promoting access to innovative anticancer medicines: a review of drug price and National reimbursement negotiation in China. Inquiry. 2023;60:469580231170729. doi: 10.1177/00469580231170729
   PubMed Web of Science ®Google Scholar